Search

Your search keyword '"Nora Navone"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Nora Navone" Remove constraint Author: "Nora Navone" Language undetermined Remove constraint Language: undetermined
40 results on '"Nora Navone"'

Search Results

1. Supplemental Figure 1 from Association of HO-1 and BRCA1 Is Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer

4. Data from Critical Role of Endogenous Heme Oxygenase 1 as a Tuner of the Invasive Potential of Prostate Cancer Cells

6. PD04-02 USING GENOMIC AND TRANSCRIPTOMIC PROPERTIES TO DETERMINE ANDROGEN RESPONSE IN DUCTAL PROSTATE CANCERS AND DETERMINE EFFICACY OF POLY(ADP-RIBOSE) POLYMERASE INHIBITORS WITH ANDROGEN SIGNALLING INHIBITORS THERAPY IN VITRO

7. Table S5-S7 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

8. Figure S3 from In Vivo Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development

9. Table S3 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

10. Table S2 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

11. Supplementary Data from Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment

12. Data from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

13. Data from Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment

14. Data from In Vivo Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development

15. Figure S1 from In Vivo Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development

17. Table S4 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

18. Figure S2 from In Vivo Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development

19. Supplementary Tables from Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment

21. Figure S1 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

22. Data from PCAT-1, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer

23. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones

24. Pin-pointing the key hubs in the IFN-γ pathway responding to SARS-CoV-2 infection

25. KDM4A promotes the progression of neuroendocrine prostate cancer

26. Abstract 142: Candidate measures of lineage plasticity in aggressive phenotypes of prostate cancer

27. Abstract 4760: KDM4A promotes NEPC progression through regulation of MYC expression

28. Targeting histone lysine demethylase KDM4A in Aggressive Variant Prostate Cancer

29. Exploiting Interdata Relationships in Prostate Cancer Proteomes: Clinical Significance of HO-1 Interactors

30. Abstract 2374: Early metabolic rewiring of prostate cancer cells triggered by bone progenitors defines survival of metastatic prostate cancer

31. Abstract 284: A 3D multicellular in vitro prostate cancer model featuring racially/ethnically diverse PDXs

32. Protein Kinase A (PKA) as a Master Regulator of the Early Metabolic Reprogramming in Bone Metastatic Prostate Cancer Cells

33. Transcriptional Inactivation of TP53 and the BMP Pathway Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer

34. Optimizing the diagnosis and management of ductal prostate cancer

36. Bone Progenitors Pull the Strings on the Early Metabolic Rewiring Occurring in Prostate Cancer Cells

37. Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer

38. Abstract 4674: Targeting cancer stem-cells in aggressive variant prostate cancers

39. Targeting prostate cancer bone metastases

40. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2

Catalog

Books, media, physical & digital resources